Latest Insider Transactions at Viracta Therapeutics, Inc. (VIRX)
This section provides a real-time view of insider transactions for Viracta Therapeutics, Inc. (VIRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Viracta Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Viracta Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+6.67%
|
-
|
|
Nov 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+2.92%
|
-
|
|
Aug 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+7.14%
|
-
|
|
Aug 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.0%
|
-
|
|
May 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,035
+7.69%
|
-
|
|
May 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.1%
|
-
|
|
Feb 27
2024
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,405
-3.22%
|
$0
$0.73 P/Share
|
|
Feb 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+8.33%
|
-
|
|
Feb 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.2%
|
-
|
|
Feb 25
2024
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+6.12%
|
-
|
|
Dec 01
2023
|
Mark Rothera President and CEO |
BUY
Open market or private purchase
|
Direct |
47,906
+32.39%
|
$0
$0.49 P/Share
|
|
Nov 30
2023
|
Mark Rothera President and CEO |
BUY
Open market or private purchase
|
Direct |
52,094
+50.0%
|
$0
$0.49 P/Share
|
|
Nov 28
2023
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,720
-3.63%
|
$0
$0.5 P/Share
|
|
Nov 25
2023
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+6.3%
|
-
|
|
Nov 25
2023
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+9.09%
|
-
|
|
Nov 25
2023
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.3%
|
-
|
|
Aug 28
2023
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,512
-3.54%
|
$3,512
$1.45 P/Share
|
|
Aug 25
2023
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+10.0%
|
-
|
|
Aug 25
2023
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.41%
|
-
|
|
Aug 25
2023
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,888
+6.49%
|
-
|
|
May 25
2023
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,035
+11.11%
|
-
|
|
May 25
2023
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.53%
|
-
|
|
May 25
2023
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,635
-3.79%
|
$3,635
$1.42 P/Share
|
|
May 25
2023
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+6.7%
|
-
|
|
Feb 27
2023
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,599
-3.89%
|
$3,599
$1.68 P/Share
|
|
Feb 27
2023
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,156
-4.29%
|
$2,156
$1.68 P/Share
|
|
Feb 25
2023
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+6.92%
|
-
|
|
Feb 25
2023
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+12.5%
|
-
|
|
Feb 25
2023
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+7.59%
|
-
|
|
Feb 25
2023
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.66%
|
-
|
|
Nov 28
2022
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,532
-3.96%
|
$7,064
$2.72 P/Share
|
|
Nov 28
2022
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,116
-4.39%
|
$4,232
$2.72 P/Share
|
|
Nov 25
2022
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+7.16%
|
-
|
|
Nov 25
2022
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.8%
|
-
|
|
Nov 25
2022
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+14.29%
|
-
|
|
Nov 25
2022
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+7.88%
|
-
|
|
Aug 26
2022
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,190
-4.73%
|
$8,760
$4.01 P/Share
|
|
Aug 26
2022
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
13,379
-2.14%
|
$53,516
$4.01 P/Share
|
|
Aug 26
2022
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,655
-4.25%
|
$14,620
$4.02 P/Share
|
|
Aug 25
2022
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+8.18%
|
-
|
|
Aug 25
2022
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.87%
|
-
|
|
Aug 25
2022
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+16.67%
|
-
|
|
Aug 25
2022
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+7.41%
|
-
|
|
May 26
2022
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,596
-4.35%
|
$3,596
$1.9 P/Share
|
|
May 26
2022
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,154
-4.86%
|
$2,154
$1.9 P/Share
|
|
May 26
2022
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
13,162
-2.14%
|
$13,162
$1.9 P/Share
|
|
May 25
2022
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+7.69%
|
-
|
|
May 25
2022
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+20.0%
|
-
|
|
May 25
2022
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+8.52%
|
-
|
|
May 25
2022
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.94%
|
-
|